Impact Factor 5.511

Among the world's top 10 most-cited Immunology journals

Correction ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2018.02606

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond

  • 1VU University Medical Center, Netherlands

Missing disclosure statement
In the original article, we neglected to disclose that authors Lisa A. King and Roeland Lameris are currently funded by Lava Therapeutics and that Hans J. van der Vliet also acts as chief scientific officer of Lava Therapeutics. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: iNKT cell, CD1d, alpha-galactosylceramide, Glycolipids, Cancer, Immunotherapy

Received: 19 Oct 2018; Accepted: 23 Oct 2018.

Edited by:

Frontiers I. Immunology Editorial Office, Frontiers Media SA, Switzerland

Copyright: © 2018 van der Vliet. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Hans J. van der Vliet, VU University Medical Center, Amsterdam, Netherlands, jj.vandervliet@vumc.nl